98%
921
2 minutes
20
Primary meningococcal conjunctivitis (PMC) is rare, and it is particularly rare in older patients. Patients with PMC may develop invasive meningococcal disease (IMD), which has an overall mortality rate of 8 %-14 %. An 81-year-old man presented to us with complaints of decreased vision and persistent pain in his right eye after ocular trauma. He had copious purulent discharge, conjunctival injection, corneal edema and Descemet's membrane folds in the right eye. The best-corrected visual acuity (BCVA) was 0.02. Levofloxacin 1.5 % eye drops and fluorometholone 0.1 % eye drops, each four times daily, were initiated before the results of conjunctival culture were available. Neisseria meningitidis was isolated 2 days after the patient's first visit. Cefmenoxime hydrochloride 0.5 % eye drops eight times daily were added and a single dose of oral levofloxacin 500 mg was administered to prevent IMD. After treatment, his symptoms resolved and BCVA increased to 0.8. The frequency of instillation of eye drops was reduced, and all medications were stopped 21 days after the first visit. The patient did not develop IMD. Later, the serogroup and sequence type of our isolate was revealed to be non-groupable and 11026, which is unique to Japan. All ST-11026 isolates have been found to lack the ability to synthesize capsular polysaccharide, which is one of the meningococcal pathogenicity. If a patient presents with conjunctivitis with copious ocular purulent discharge, conjunctival culture should be performed promptly for early diagnosis of PMC regardless of the patient's age.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jiac.2025.102702 | DOI Listing |
Ophthalmol Glaucoma
September 2025
Department of Ophthalmology and Visual Sciences, University of Michigan W.K. Kellogg Eye Center, Ann Arbor, Michigan. Electronic address:
Purpose: To investigate hand function and eye drop instillation success in adults with and without glaucoma.
Design: Cross-sectional pilot study.
Subjects: Adults aged ≥ 65 years with glaucoma who use eye drops daily and adults aged 65+ without glaucoma who do not regularly use eye drops.
Zhonghua Yan Ke Za Zhi
September 2025
Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha 410015, China.
As the world's leading irreversible blinding eye disease, glaucoma is predominantly managed with pharmaceutical interventions in clinical practice. However, long-term use of traditional eye drops containing preservatives (e.g.
View Article and Find Full Text PDFAdv Ther
September 2025
Centre d'Ophtalmologie Visis, 66000, Perpignan, France.
Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.
Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma.
Vestn Oftalmol
September 2025
Azerbaijan Medical University, Baku, Azerbaijan.
Objective: This study evaluated changes in ocular parameters in patients with progressive myopia receiving 0.01% atropine.
Material And Methods: The study included 35 children (18 girls, 51.
Transl Vis Sci Technol
September 2025
Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Purpose: The purinergic receptor P2X4 is critical to transduction of ocular pain. The aim of this study was to investigate the therapeutic potential of the P2X4 receptor antagonist BAY-776 in alleviating chronic ocular pain.
Methods: Chronic ocular pain was induced in male rats (8-9 weeks old; n = 12 per group) via double lacrimal gland removal (DLGR).